Advertising in the Indian Journal of Chest Diseases and Allied Sciences: A Media Planner's Guide to IJCDAS Print and Digital Ad Placement

Most pharmaceutical and medical device companies we speak with have never seriously considered placing an advertisement in a specialist pulmonary medicine journal — and that, frankly, is a missed opportunity that surprises us every time. The Indian Journal of Chest Diseases and Allied Sciences reaches a concentrated audience of chest physicians, pulmonologists, and respiratory specialists across India, which means every impression your brand earns here is earned in front of someone who can actually prescribe, recommend, or procure what you are selling. That kind of targeting precision is genuinely difficult to replicate at comparable cost across any other media channel.

What Is the Indian Journal of Chest Diseases and Allied Sciences (IJCDAS)?

Few medical journals in India carry the institutional weight that the Indian Journal of Chest Diseases and Allied Sciences does, and that weight matters enormously when you are trying to place a brand in an environment that clinicians actually trust. Founded under the auspices of the Vallabhbhai Patel Chest Institute at the University of Delhi in New Delhi, IJCDAS has been publishing original research articles, review articles, case reports, and book reviews related to chest medicine, pulmonary medicine, and respiratory disease for decades. The journal carries the ISSN 0377-9343, which is the identifier you will need when referencing it in your media plan or purchase order documentation.

The journal is published by Jaypee Brothers Medical Publishers (P) Ltd — one of India's most established medical publishers, headquartered on Ansari Road in Daryaganj, New Delhi — and is officially associated with the National College of Chest Physicians India, which lends it a professional credibility that goes well beyond a typical academic publication. IJCDAS is indexed in PubMed, listed in the DOAJ (Directory of Open Access Journals), and carries a measurable SCImago Journal Rank (SJR), which signals to both the academic community and prospective advertisers that the editorial standards here are not casual. The journal operates under a CC BY-NC 4.0 license for its open-access content, and its digital archive benefits from Portico digital preservation, ensuring long-term accessibility of both editorial and advertising content.

What a lot of people miss is that IJCDAS is a quarterly journal, which means there are four discrete ad schedule windows per year — and those windows fill up faster than most first-time advertisers expect. The journal covers the full spectrum of chest diseases and allied sciences, including conditions like COPD, asthma, tuberculosis, lung cancer, and pulmonary rehabilitation, which creates natural contextual adjacency opportunities for pharmaceutical advertisers whose products address these specific therapeutic areas. At SmartAds, we always tell our clients that contextual placement in a peer-reviewed journal like this one is not just about eyeballs — it is about the professional credibility that rubs off on your brand by association.

Why Should Pharma and Healthcare Brands Advertise in IJCDAS?

The honest answer is that most brands advertising in mass media — television, outdoor, even digital — are paying to reach an enormous number of people who will never influence a respiratory drug prescription. Magazine advertising in a specialist medical journal like the Indian Journal of Chest Diseases and Allied Sciences inverts that equation entirely; the audience is smaller, but the concentration of clinical decision-makers is extraordinarily high. Pulmonologists, chest physicians, respiratory therapists, and academic researchers in chest medicine form the core readership of IJCDAS, which means a full-page print advertisement here is essentially a direct conversation with the people who matter most to a respiratory pharma brand.

We have found, across campaigns we have managed for pharmaceutical clients, that the cost-per-relevant-impression in specialist medical journals works out to be surprisingly competitive when you account for audience quality rather than raw numbers. A retail media buyer focused purely on CPM will always prefer a mass-market channel, but a brand manager at a company selling an inhaler device or a COPD management therapy has a fundamentally different ROI equation to solve. Respiratory pharma companies in India — and brands in categories adjacent to chest medicine, including diagnostic equipment manufacturers and medical device companies — have historically treated IJCDAS as a cornerstone of their targeted medical audience strategy, precisely because the readership is self-selected and professionally engaged.

On top of that, the association with Vallabhbhai Patel Chest Institute and the National College of Chest Physicians India gives IJCDAS a prestige that general-circulation medical journals simply cannot match for this specific therapeutic category. VPCI is one of India's foremost institutions for chest medicine research, and the journal's editorial board reflects that pedigree. When we advise clients on pharmaceutical advertising in medical journals in India, we consistently find that brands which appear in IJCDAS are perceived differently by the clinicians who see them — the environment signals that the advertiser takes pulmonary medicine seriously, which is a brand positioning advantage that is genuinely hard to put a price on.

What Types of Advertisements Does IJCDAS Accept?

IJCDAS accepts both print advertisement and digital advertisement placements, which gives advertisers meaningful flexibility depending on their campaign objectives and budget structure. On the print side, the standard formats include full-page advertisements, half-page advertisements, inside front cover placements, inside back cover placements, and back cover placements — each of which carries different rates and different levels of reader visibility. The back cover and inside covers are the premium positions in any quarterly journal, and they tend to be booked well in advance by recurring advertisers; first-time advertisers who approach the booking process late in the ad schedule cycle often find these positions already committed.

Beyond standard display advertising, IJCDAS through Jaypee Brothers Medical Publishers also accommodates sponsored supplement and reprint services, which we will address in more detail later in this piece. For digital advertisement placements, the journal's online presence through JaypeeDigital and the DOAJ-indexed open-access platform creates opportunities for banner advertising and digital brand placements that reach the journal's online readership — which, given PubMed indexing and open-access availability, extends well beyond the print subscriber base. The specific banner sizes, file format requirements, and resolution specifications for digital advertisement materials are confirmed at the time of booking with the Jaypee Brothers advertising team, and we strongly recommend requesting a current media kit when initiating any ad booking conversation.

What we tell our clients is that the choice between print and digital placement in a journal like IJCDAS should not be treated as an either-or decision; the two formats reach overlapping but distinct segments of the readership, and a combined placement — particularly for a product launch or a major therapeutic indication expansion — tends to deliver meaningfully better brand recall than either format alone. Drug advertisement placements in particular benefit from the print format's permanence; a clinician who reads a peer-reviewed journal in print is far more likely to spend time with a well-designed full-page advertisement than one who is scrolling through a digital PDF.

How Do I Book a Print or Digital Advertisement in IJCDAS?

The ad booking process for the Indian Journal of Chest Diseases and Allied Sciences runs through Jaypee Brothers Medical Publishers, which manages all commercial advertising relationships for the journal. The process begins with a formal inquiry to the Jaypee Brothers advertising team — typically via their office at Ansari Road, Daryaganj, New Delhi — where prospective advertisers request the current rate card, confirm available positions in the upcoming issue, and receive the advertiser guidelines document that specifies all technical and compliance requirements. At SmartAds, we handle this initial outreach on behalf of our clients, which saves considerable back-and-forth time and ensures that the brief we submit is already formatted to the publisher's requirements.

Once the position and format are confirmed, the advertiser is required to submit a formal purchase order along with the advertisement material — which must meet the technical specifications provided by Jaypee Brothers for the relevant format. For pharmaceutical advertising specifically, additional documentation is required at this stage, including proof of marketing authorization for the product being advertised; this is a non-negotiable requirement that reflects both the editorial independence policy of IJCDAS and the regulatory framework governing drug advertisement in India. We have seen this backfire when clients assume the documentation step is a formality — it is not, and incomplete submissions can result in a missed issue deadline.

The payment process follows confirmation of the booking, and the invoice issued by Jaypee Brothers Medical Publishers will reflect the applicable GST on advertisement at the current rate. Advertisers should ensure their accounts team is prepared to process payment promptly, as the ad schedule for a quarterly journal operates on tight timelines; a delayed payment can jeopardize a confirmed position, particularly for premium placements like the back cover or inside front cover. International companies advertising in IJCDAS should additionally confirm currency and wire transfer arrangements with Jaypee Brothers at the time of booking, since invoicing conventions for non-INR payments may differ from domestic advertiser processes.

What Are the Ad Submission Deadlines and Scheduling Guidelines?

The quarterly journal format of IJCDAS means that advertisement material submission deadlines are fixed and genuinely inflexible — a reality that catches a surprising number of first-time advertisers off guard. As a general rule, advertisement material must be submitted approximately four weeks prior to the print date of each issue, which gives the production team adequate time to integrate the ad into the layout, run quality checks, and make any corrections before the issue goes to press. Missing this window by even a few days typically means waiting for the next quarterly issue, which in practical terms means a three-month delay — a significant cost in any time-sensitive campaign context.

The four issues of IJCDAS are published across the calendar year, with each issue covering a quarter; the precise publication months and corresponding submission deadlines are confirmed annually by Jaypee Brothers Medical Publishers and should be requested as part of the initial ad booking conversation. What we recommend to clients planning a full-year campaign is to book all four positions at the start of the year, which secures preferred placements and often provides leverage for negotiating a more favorable overall rate. A pharmaceutical client we worked with on a respiratory portfolio campaign — a mid-sized company with products across the COPD and asthma categories — did exactly this, booking a full-year inside back cover position across all four quarterly issues, and the consistency of presence across the full volume year generated measurably stronger brand recall among the pulmonologist audience they were targeting.

On top of the submission deadline for advertisement material, advertisers should also factor in the time required to produce print-ready artwork that meets Jaypee's technical specifications — particularly for first-time advertisers whose creative teams may not be familiar with the resolution, bleed, and color profile requirements for medical journal print production. Digital advertisement materials have their own separate specifications, and the two sets of requirements are not interchangeable. At SmartAds, our production team manages this specification compliance process as part of the end-to-end campaign management service we provide, which eliminates a common source of last-minute delays.

What Are the Payment Terms for IJCDAS Magazine Advertising?

Payment terms for advertising placed through Jaypee Brothers Medical Publishers are structured around advance payment or payment against confirmed purchase order, which is standard practice for medical journal advertising in India. The invoice will be raised in Indian rupees for domestic advertisers, and the total payable amount will include the base advertisement rate plus 18% GST as applicable under the GST on advertisement framework — classified under SAC code 998361, which covers print and digital advertising services. Advertisers whose accounts teams are unfamiliar with the GST treatment of magazine advertising sometimes flag this as a surprise on the invoice, so we always brief our clients on the total cost-inclusive figure upfront to avoid any approval delays on the finance side.

Accepted payment methods typically include bank transfer (NEFT/RTGS) and demand draft, which is consistent with how most Indian medical publishers manage commercial transactions; digital payment options may also be available and should be confirmed directly with the Jaypee Brothers accounts team at the time of booking. For agency bookings — where SmartAds or another media agency is placing the advertisement on behalf of a client — the purchase order should clearly identify both the agency and the end advertiser, along with the GST registration numbers of all relevant parties to ensure clean input tax credit documentation.

Frankly speaking, the payment process for IJCDAS advertising is straightforward once the initial booking is confirmed; the complexity, if any, tends to arise on the advertiser's internal side rather than the publisher's. Large pharmaceutical companies in particular sometimes face extended internal purchase order approval cycles which, when not anticipated early enough, can result in a confirmed position being released back to the market. We have seen this happen more than once, and our standard advice is to initiate the internal finance approval process at the same time as the editorial booking — not after.

How Does IJCDAS Ensure Editorial Independence from Advertisers?

This is a question we get asked more often than you might expect, particularly from pharmaceutical advertising clients who are acutely aware of the reputational risks associated with perceived commercial influence over clinical content. The Indian Journal of Chest Diseases and Allied Sciences maintains a clear policy of editorial independence, which means that the editorial board — operating under the institutional authority of Vallabhbhai Patel Chest Institute and the University of Delhi — retains full and exclusive control over which original research articles, review articles, and case reports are published. No advertiser, regardless of the size of their investment, has any influence over editorial decisions, and this is a non-negotiable condition of advertising in the journal.

The practical implication of this policy for advertisers is that placement adjacency to specific clinical content cannot be guaranteed in the same way it might be in a controlled digital advertising environment; while you can request that your advertisement appear in proximity to content related to, say, COPD management or tuberculosis treatment, the final placement is determined by the production team in accordance with editorial layout requirements. This is not unique to IJCDAS — it is standard practice across peer-reviewed journals globally, and it is actually a feature rather than a limitation, because the editorial independence policy is precisely what gives the journal its credibility and, by extension, gives your advertisement a credible environment in which to appear.

At SmartAds, we always tell our clients that the editorial independence of a peer-reviewed journal like IJCDAS is one of the most valuable things they are paying for when they book magazine advertising here. The clinicians who read this journal trust its content because they know it has not been commercially compromised; that trust extends, at least partially, to the brands that appear within its pages. It is a fundamentally different dynamic from, say, a sponsored social media post, and it deserves to be valued accordingly in the media plan.

What Products or Services Cannot Be Advertised in IJCDAS?

The advertiser guidelines for IJCDAS, as administered by Jaypee Brothers Medical Publishers, reflect both the journal's professional standards and the broader regulatory framework governing advertising in Indian medical publications. Drug advertisements are accepted, but they must comply with all applicable regulations under the Drugs and Magic Remedies (Objectionable Advertisements) Act and related Ministry of Health and Family Welfare guidelines — which means the advertised product must hold a valid marketing authorization in India, and the advertisement content must not make claims that exceed what the approved product labeling permits. This documentation requirement is enforced at the submission stage, and advertisements that cannot be supported by appropriate regulatory documentation will not be accepted.

Products or services that are not relevant to the clinical and professional audience of a chest medicine journal — consumer goods, financial services, non-medical lifestyle products — are generally not accepted, since they would be inconsistent with the journal's professional character and its editorial independence commitments. Similarly, advertisements that make misleading therapeutic claims, that reference unapproved indications, or that are structured in a way that could be confused with editorial content are not permitted. The distinction between an advertisement and editorial content must be visually clear in the final published layout, which is a standard requirement across all Jaypee Brothers journals.

The thing is, for the vast majority of legitimate pharmaceutical and medical device advertisers in the respiratory and chest medicine space, none of these restrictions present any practical obstacle. Companies like those operating in the inhaler advertising India market — brands with products for asthma, COPD, tuberculosis, or lung cancer — will find that IJCDAS's advertiser guidelines are entirely consistent with their standard regulatory compliance processes. Where we have occasionally seen friction is with smaller companies that attempt to advertise products whose regulatory status in India is ambiguous; in those cases, the publisher's documentation requirements serve as a useful filter that protects the journal's credibility.

Are Sponsored Supplements and Reprints Available in IJCDAS?

Sponsored supplements represent one of the more strategically interesting advertising options available through Jaypee Brothers Medical Publishers, and they are significantly underutilized by most of the respiratory pharma companies we work with. A sponsored supplement is essentially a separately produced issue or section of the journal, funded by a single advertiser or a consortium of sponsors, which contains clinical content — typically proceedings from a symposium, a consensus statement, or a collection of review articles on a specific therapeutic topic — that is relevant to the sponsor's area of interest. The editorial content of a sponsored supplement is still subject to independent editorial oversight, but the sponsor has the opportunity to associate their brand with a body of clinically credible content in a way that a standard display advertisement simply cannot achieve.

Reprint services are a related offering through Jaypee Brothers, whereby an advertiser can commission high-quality reprints of specific articles from IJCDAS — typically original research articles or review articles that are favorable to a particular therapeutic approach — for distribution to health care professionals as part of a medical affairs or scientific communication program. E-print versions of reprints are also available, which can be distributed digitally through medical representative channels or at conferences. The cost of reprint services varies depending on quantity and format, and the terms are negotiated directly with Jaypee Brothers at the time of the request.

One pharmaceutical client we worked with — a company with a significant presence in the pulmonary rehabilitation and COPD management space — commissioned a sponsored supplement through IJCDAS as part of a major product lifecycle extension campaign; the supplement covered emerging evidence in pulmonary rehabilitation, which was directly relevant to the product's positioning, and was distributed both as part of the regular journal mailing and as standalone reprints at a national chest medicine conference. The brand visibility generated by that supplement — among a targeted medical audience of chest physicians and pulmonologists — was, by the client's own assessment, equivalent to several years of standard display advertising at a fraction of the cost. That is the kind of outcome that makes sponsored supplement investment genuinely worth evaluating.

What Is the Readership Profile of IJCDAS — Who Will See My Advertisement?

The readership of the Indian Journal of Chest Diseases and Allied Sciences is, by design, one of the most concentrated specialist audiences in Indian medical publishing. The primary readership consists of pulmonologists, chest physicians, and respiratory medicine specialists — clinicians who are directly involved in diagnosing and managing conditions including COPD, asthma, tuberculosis, lung cancer, and other chest diseases. Secondary readership includes general physicians with a strong interest in respiratory disease, academic researchers at institutions affiliated with the University of Delhi and other Indian medical universities, and members of the National College of Chest Physicians India, which is one of the journal's institutional sponsors.

What a lot of people miss when evaluating the readership of a quarterly journal like IJCDAS is that the effective reach extends well beyond the direct subscriber count. Because the journal is indexed in PubMed and listed in the DOAJ as an open access journal, individual articles — and by extension, the advertisements placed adjacent to them — are accessible to a global audience of researchers and clinicians who encounter the content through database searches. The Portico digital preservation archive further ensures that this content remains accessible over time, which means a print advertisement placed in IJCDAS has a digital afterlife that most print media placements simply do not. For pharmaceutical advertising and medical device marketing, this extended reach into an international research audience is a genuine bonus that is rarely factored into the initial ROI calculation.

VPCI's institutional affiliation gives IJCDAS particular credibility among the academic and research community, while the NCCP(I) association ensures strong penetration among practicing chest physicians across India. For respiratory pharma companies targeting the prescriber base in India — whether they are established players like Cipla with its respiratory portfolio or newer entrants in the inhaler advertising India market — the combination of academic credibility and practicing clinician reach makes IJCDAS a genuinely distinctive media channel. We consistently find, when we benchmark IJCDAS against other Indian respiratory and pulmonary medicine journals in terms of audience quality, that the institutional pedigree of VPCI and the University of Delhi gives it a differentiated positioning that is difficult to replicate.

Advertising Rates, GST Compliance, and What to Budget

Jaypee Brothers Medical Publishers does not publish a publicly available rate card for IJCDAS magazine advertising on their website — which is, frankly, one of the most significant information gaps that prospective advertisers encounter when researching this channel. Based on our experience managing medical journal advertising placements in India, and benchmarking against comparable peer-reviewed journals published by Jaypee and other Indian medical publishers, the cost of a full-page print advertisement in a specialist quarterly journal of this caliber works out to somewhere in the ballpark of ₹30,000 to ₹80,000 per issue, depending on position and negotiated terms — with premium positions like the back cover and inside front cover commanding rates at the higher end of that range or beyond. These figures are indicative benchmarks, and actual rates should be confirmed directly with Jaypee Brothers at the time of booking.

The GST treatment of magazine advertising in India is an area where we see a lot of confusion among first-time advertisers, particularly those whose media buying experience is primarily in digital or broadcast channels. Magazine advertising — including advertising in medical journals — attracts 18% GST under the applicable SAC code 998361, which covers print and digital advertising services. This means that a ₹50,000 advertisement placement will carry an additional GST liability of ₹9,000, bringing the total invoice value to ₹59,000; this is the number that needs to appear in your media budget approval, not the base rate. At SmartAds, we always present our clients with GST-inclusive cost estimates from the outset, because a surprise tax line on the final invoice is the kind of thing that erodes trust in the planning process.

For advertisers placing multiple insertions across the four quarterly issues of IJCDAS, or combining print advertisement with digital advertisement placements, there is often room to negotiate a package rate that improves the overall cost efficiency of the campaign. The FICCI-EY Media and Entertainment Report has consistently noted that print advertising in specialist professional publications maintains stronger rate integrity than general-circulation print, which means aggressive discounting is less common here than in newspaper or mass-market magazine advertising; that said, multi-issue commitments do typically attract more favorable terms than single-issue bookings. We handle these negotiations on behalf of our clients as part of the standard SmartAds media buying service.

FAQ: Everything Advertisers Ask About IJCDAS Magazine Advertising

Q: How can I book an advertisement in the Indian Journal of Chest Diseases and Allied Sciences?

The ad booking process runs through Jaypee Brothers Medical Publishers, which manages all commercial advertising for IJCDAS. The process begins with a formal inquiry to their office at Ansari Road, Daryaganj, New Delhi, where you request the current rate card, confirm available positions in the upcoming quarterly issue, and receive the advertiser guidelines document. Once a position is confirmed, you submit a purchase order along with your advertisement material and any required regulatory documentation. At SmartAds, we manage this entire process on behalf of clients — from initial inquiry through to final artwork submission — which ensures nothing falls through the cracks on the tight deadline timelines that a quarterly journal operates on.

Q: What types of advertisements are accepted in IJCDAS — print, digital, or both?

IJCDAS accepts both print advertisement and digital advertisement placements. Print formats include full-page, half-page, back cover, inside front cover, and inside back cover positions. Digital placements are available through the journal's online presence on JaypeeDigital and the open-access platform, with banner advertising and digital brand placements available for the online readership. Sponsored supplements and reprint services are also available for advertisers looking for deeper content integration. The specific technical specifications for each format — including file types, resolution requirements, and banner dimensions for digital advertisement materials — are provided by Jaypee Brothers at the time of booking.

Q: What are the advertisement submission deadlines for IJCDAS?

As a quarterly journal, IJCDAS operates on four fixed ad schedule windows per year, with advertisement material typically required approximately four weeks prior to the print date of each issue. The precise deadlines for each quarterly issue are confirmed annually by Jaypee Brothers Medical Publishers and should be requested as part of the initial booking conversation. Missing the submission deadline for a given issue means waiting for the following quarter, so early engagement with the booking process is strongly recommended — particularly for premium positions like the back cover, which tend to be committed well in advance.

Q: Who publishes the Indian Journal of Chest Diseases and Allied Sciences?

IJCDAS is published by Jaypee Brothers Medical Publishers (P) Ltd, one of India's most established medical publishers, headquartered on Ansari Road in Daryaganj, New Delhi. The journal is associated with the Vallabhbhai Patel Chest Institute at the University of Delhi and the National College of Chest Physicians India. All commercial advertising inquiries, including rate card requests and booking confirmations, are handled through Jaypee Brothers.

Q: Are drug or pharmaceutical product advertisements allowed in IJCDAS?

Yes, drug advertisements and pharmaceutical advertising are accepted in IJCDAS, subject to compliance with applicable Indian regulations governing drug advertisement — including the Drugs and Magic Remedies (Objectionable Advertisements) Act and Ministry of Health and Family Welfare guidelines. Pharmaceutical advertisers are required to provide proof of marketing authorization for the product being advertised, and the advertisement content must not make claims that exceed the approved product labeling. These requirements are enforced at the submission stage, and advertisements that cannot be supported by appropriate documentation will not be accepted.

Q: What payment methods are accepted for IJCDAS magazine advertising?

Payment for IJCDAS advertising is typically processed through bank transfer (NEFT/RTGS) or demand draft, which is standard for Indian medical publishers. The invoice will include the base advertisement rate plus 18% GST under SAC code 998361. For agency bookings, the purchase order should clearly identify both the agency and the end advertiser, along with the GST registration numbers of all relevant parties. International advertisers should confirm currency and wire transfer arrangements directly with Jaypee Brothers at the time of booking.

Q: Does IJCDAS offer sponsored supplement or reprint advertising options?

Yes, both sponsored supplement and reprint services are available through Jaypee Brothers Medical Publishers. A sponsored supplement allows a brand to associate with a body of independently produced clinical content on a specific therapeutic topic — such as COPD management, tuberculosis treatment, or pulmonary rehabilitation — in a format that carries significantly more clinical credibility than standard display advertising. Reprint services allow advertisers to commission high-quality print or e-print copies of specific published articles for distribution through medical representative channels or at conferences. Terms and pricing for both services are negotiated directly with Jaypee Brothers.

Q: What is the readership profile of IJCDAS — who will see my advertisement?

The core readership of IJCDAS consists of pulmonologists, chest physicians, and respiratory medicine specialists across India, along with academic researchers affiliated with institutions including VPCI and the University of Delhi, and members of the National College of Chest Physicians India. Because the journal is indexed in PubMed and listed in the DOAJ as an open access journal, the digital readership extends to an international audience of researchers and clinicians who access content through database searches. For pharmaceutical advertising targeting the prescriber base in chest medicine and respiratory disease, this combination of domestic clinical reach and international research visibility makes IJCDAS a genuinely distinctive channel.

Q: What GST rate applies to advertising in Indian medical journals like IJCDAS?

Magazine advertising in India, including advertising in medical journals like the Indian Journal of Chest Diseases and Allied Sciences, attracts 18% GST under SAC code 998361, which covers print and digital advertising services. Advertisers should ensure that their budget approvals reflect the GST-inclusive total, not just the base advertisement rate, to avoid invoice surprises. Input tax credit on GST paid for advertising is generally available to GST-registered advertisers, subject to standard ITC eligibility conditions.

Q: Can international companies advertise in the Indian Journal of Chest Diseases and Allied Sciences?

Yes, international companies can advertise in IJCDAS, and the journal's PubMed indexing and open-access status make it a relevant channel for global pharmaceutical and medical device companies with products registered in India. International advertisers should confirm currency and payment arrangements with Jaypee Brothers Medical Publishers at the time of booking, as invoicing conventions for non-INR payments may differ from domestic advertiser processes. Marketing authorization documentation requirements apply equally to international advertisers — products must be approved for marketing in India to be advertised in the journal.

Q: Are there any products or services that cannot be advertised in IJCDAS?

Products that do not hold valid marketing authorization in India cannot be advertised, nor can products whose advertisement would violate the Drugs and Magic Remedies Act or Ministry of Health and Family Welfare guidelines. Non-medical consumer products, financial services, and lifestyle products that are inconsistent with the journal's professional character are generally not accepted. Advertisements that make misleading therapeutic claims, reference unapproved indications, or could be confused with editorial content are also not permitted under the journal's advertiser guidelines.

Q: How does IJCDAS maintain editorial independence from its advertisers?

The editorial board of IJCDAS, operating under the institutional authority of Vallabhbhai Patel Chest Institute and the University of Delhi, retains full and exclusive control over all editorial content — including original research articles, review articles, and case reports. No advertiser has any influence over editorial decisions, and the distinction between advertising and editorial content must be visually clear in the published layout. This editorial independence policy is a non-negotiable condition of advertising in the journal and is one of the primary reasons the journal carries the credibility it does among its clinical readership.

Q: What is the publication frequency of IJCDAS and when are ad slots available?

IJCDAS is a quarterly journal, published four times per year. This means there are four ad schedule windows annually, each with its own submission deadline and publication date. The specific issue dates and corresponding submission deadlines are confirmed annually by Jaypee Brothers Medical Publishers. Advertisers planning a full-year campaign are advised to book all four positions at the start of the year to secure preferred placements and maximize campaign consistency.

Q: Is IJCDAS indexed in PubMed, DOAJ, or other major databases?

Yes, the Indian Journal of Chest Diseases and Allied Sciences is indexed in PubMed (via NCBI), listed in the DOAJ (Directory of Open Access Journals), and carries a measurable SCImago Journal Rank (SJR). The journal's digital archive is preserved through Portico digital preservation, ensuring long-term accessibility. These indexing credentials are significant for advertisers because they extend the journal's effective reach well beyond its direct subscriber base to the global community of researchers and clinicians who access content through these databases.

Q: What documents are required from pharmaceutical advertisers to place an ad in IJCDAS?

Pharmaceutical advertisers are required to provide proof of marketing authorization for the product being advertised — typically a copy of the product's drug license or approval documentation from the relevant Indian regulatory authority. The advertisement content itself must comply with approved product labeling and must not make claims that exceed what the marketing authorization permits. These documents are submitted along with the purchase order and advertisement material as part of the standard ad booking process; incomplete documentation at the submission stage will result in the advertisement not being accepted for the relevant issue.

Planning Your IJCDAS Campaign: A Closing Perspective from SmartAds

Medical journal advertising is, in our experience, one of the most consistently undervalued channels in the media plans of pharmaceutical and healthcare brands in India — and the Indian Journal of Chest Diseases and Allied Sciences represents a particularly strong case for reconsideration. The combination of institutional credibility from VPCI and the University of Delhi, professional association reach through the National College of Chest Physicians India, PubMed and DOAJ indexing that extends the audience internationally, and a readership that is almost entirely composed of clinical decision-makers in chest medicine and respiratory disease creates a media environment that is genuinely difficult to replicate at comparable cost in any other channel.

The thing is, the brands that get the most out of IJCDAS are not the ones that treat it as a one-off insertion; they are the ones that commit to a sustained presence across multiple quarterly issues, combine print advertisement with digital advertisement placements, and explore the deeper integration opportunities that sponsored supplement and reprint services offer. A respiratory pharma company that appears consistently in IJCDAS across a full volume year — with well-designed, compliant drug advertisement creative that respects the journal's professional environment — builds a cumulative brand visibility among pulmonologists and chest physicians that compounds over time in a way that episodic advertising never does.

At SmartAds, we work with pharmaceutical companies, medical device manufacturers, and healthcare brands across India to plan and execute medical journal advertising campaigns that are strategically sound, operationally smooth, and fully compliant with all applicable regulatory and GST requirements. Our experience managing ad bookings through Jaypee Brothers Medical Publishers, combined with our broader media planning capabilities across 500+ Indian cities and multiple channels, means we can position IJCDAS advertising within a larger integrated campaign framework rather than treating it as a standalone placement. If you are evaluating the Indian Journal of Chest Diseases and Allied Sciences as part of your next media plan — or if you want an honest assessment of how it compares to other medical journals in the respiratory and chest medicine space — we would be glad to work through the numbers with you. Reach out to the SmartAds team at SmartAds.in for a customised media plan that reflects your brand's specific objectives, budget, and target audience among health care professionals in India.